Cambridge, United Kingdom
Broken String Biosciences, founded in 2020, is a UK-based biotechnology startup revolutionizing the cell and gene therapy landscape. Their innovative technology platform, INDUCE-seq®, aims to transform potential genetic "breaks" into groundbreaking therapies, aligning with their slogan, "Turning breaks into breakthroughs."
INDUCE-seq® is a next-generation sequencing (NGS)-based platform that provides crucial insights for optimizing the safety and precision of gene editing. It allows biotechnology firms to map DNA breaks and identify off-target effects with unprecedented specificity, offering actionable data throughout the discovery, pre-clinical, and clinical stages.
In October 2025, the company secured a €5.40M Series A funding round, emphasizing the growing confidence in their technology. This strategic investment underscores the platform's potential to drive advancements in the Biotechnology and Health Care industries. Investors should note the company's promise in delivering safer, more efficient gene therapies.
